BHV-0223

Drug Name: BHV-0223
Company: Biohaven Phamaceuticals
Website: http://biohavenpharma.com/
Drug Type: Small Molecule
Conditions: ALS, Alzheimer’s Disease, Ataxia, Anxiety disorders, Affective disorders, Dementia, Dystonia, Rett Syndrome, Tinnitus
Mechanism Type: Glutamate Excitotoxicity Blocker
Mechanism: BHV-0223 is a new form of riluzole that is easier to swallow. The drug, like riluzole, aims to protect motor neurons from further damage by reducing glutamate release from axon terminals.
U.S. Status for ALS: IND

References:
[1] Biohaven Announces Orphan Drug Designation Request Granted For BHV-0223 in the Treatment of Amyotrophic Lateral Sclerosis PR Newswire. December 9, 2016

Last updated February 8th, 2018

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail